Abstract: This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects.
Type:
Grant
Filed:
April 22, 2013
Date of Patent:
October 11, 2016
Assignee:
AdvanCell Diagnosztika Kft.
Inventors:
Balázs Sarkadi, György Várady, Ildikó Kasza
Abstract: This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects.
Type:
Application
Filed:
April 22, 2013
Publication date:
April 23, 2015
Applicant:
AdvanCell Diagnosztika Kft.
Inventors:
Balázs Sarkadi, György Várady, Ildikó Kasza